ISSN: 0973-7510

E-ISSN: 2581-690X

Short Communication | Open Access
Sirwan Khalid Ahmed1,2
1Department of Pediatric, Rania Pediatric & Maternity Teaching Hospital, Rania, Sulaimani, Kurdistan region, 46012, Iraq.
2Department of Nursing, University of Raparin, Rania, Sulaimani, Kurdistan region, 46012, Iraq.
Article Number: 8273 | © The Author(s). 2022
J Pure Appl Microbiol. 2022;16(suppl 1):3189-3191. https://doi.org/10.22207/JPAM.16.SPL1.15
Received: 26 November 2022 | Accepted: 27 December 2022 | Published online: 30 December 2022
Issue online: 30 December 2022
Abstract

A sudden increase in human monkeypox infections that began in non-endemic nations in May 2022 has sparked concerns about a new global infectious threat. The number of people who are vulnerable to infection with MPXV is growing worldwide. On July 23, 2022, the World Health Organization (WHO) announced that the recent outbreaks of monkeypox (MPX), an infectious sickness caused by the monkeypox virus (MPXV), have been declared a global public health emergency. As of November 26, 2022, there have been 80.850 confirmed cases and 55 deaths across 110 countries and territories. The present report highlights recommendations for prevention, vaccination, management, and infection control of the probable monkeypox outbreak.

Keywords

Monkeypox, Monkeypox Virus, Vaccination, Treatment, Management, Infection Control

Article Metrics

Article View: 850

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.